MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT

A subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of poor general condition and comorbid illness. After v...

Full description

Bibliographic Details
Main Authors: Deepak Kumar Shukla, Satyendra Katewa, Ravikant Porwal, Ravi Dara, Lalit Sharma, Rahul Sharma, Aadesh Arora
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Leukemia Research Reports
Subjects:
AML
Unfit
Azacitidine
Venetoclax
Young
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048921000340
id doaj-38f594ff06174e048ab8fa967e815a20
record_format Article
spelling doaj-38f594ff06174e048ab8fa967e815a202021-09-13T04:13:57ZengElsevierLeukemia Research Reports2213-04892021-01-0116100267MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCTDeepak Kumar Shukla0Satyendra Katewa1Ravikant Porwal2Ravi Dara3Lalit Sharma4Rahul Sharma5Aadesh Arora6Consultant Medical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital Jaipur, India; Corresponding author.Consultant - Pediatric Hematology Oncology & Bone Marrow Transplant, Manipal Comprehensive Cancer Center , Manipal Hospital Jaipur, IndiaConsultant -Infectious Disease Manipal Hospital Jaipur, IndiaConsultant Immunohematology and Transfusion Medicine Manipal Hospital Jaipur, IndiaConsultant Medical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital Jaipur, IndiaConsultant - Pediatric Hematology Oncology & Bone Marrow Transplant, Manipal Comprehensive Cancer Center , Manipal Hospital Jaipur, IndiaSenior Resident , Pediatric Hematology Oncology & Bone Marrow Transplant, Manipal Comprehensive Cancer Center , Manipal Hospital Jaipur, IndiaA subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of poor general condition and comorbid illness. After venetoclax and azacitidine patient was negative for measurable residual disease but developed cerebellar toxicity after high dose cytarabine. He underwent successful matched sibling allogeneic stem cell transplant and is presently on routine follow up. This case report suggest possible role of this combination even in young patients unfit for intensive induction.http://www.sciencedirect.com/science/article/pii/S2213048921000340AMLUnfitAzacitidineVenetoclaxYoung
collection DOAJ
language English
format Article
sources DOAJ
author Deepak Kumar Shukla
Satyendra Katewa
Ravikant Porwal
Ravi Dara
Lalit Sharma
Rahul Sharma
Aadesh Arora
spellingShingle Deepak Kumar Shukla
Satyendra Katewa
Ravikant Porwal
Ravi Dara
Lalit Sharma
Rahul Sharma
Aadesh Arora
MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
Leukemia Research Reports
AML
Unfit
Azacitidine
Venetoclax
Young
author_facet Deepak Kumar Shukla
Satyendra Katewa
Ravikant Porwal
Ravi Dara
Lalit Sharma
Rahul Sharma
Aadesh Arora
author_sort Deepak Kumar Shukla
title MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_short MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_full MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_fullStr MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_full_unstemmed MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
title_sort mrd negative cr after azacitidine and venetoclax in a young patient with aml, unfit for intensive induction followed by asct
publisher Elsevier
series Leukemia Research Reports
issn 2213-0489
publishDate 2021-01-01
description A subset of AML patients are unfit for 7+3 induction at the time of diagnosis. Present case highlights the use of azacitidine and venetoclax in a patient with intermediate risk AML with WT-1 mutation,deemed unfit for intensive induction in view of poor general condition and comorbid illness. After venetoclax and azacitidine patient was negative for measurable residual disease but developed cerebellar toxicity after high dose cytarabine. He underwent successful matched sibling allogeneic stem cell transplant and is presently on routine follow up. This case report suggest possible role of this combination even in young patients unfit for intensive induction.
topic AML
Unfit
Azacitidine
Venetoclax
Young
url http://www.sciencedirect.com/science/article/pii/S2213048921000340
work_keys_str_mv AT deepakkumarshukla mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT satyendrakatewa mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT ravikantporwal mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT ravidara mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT lalitsharma mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT rahulsharma mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
AT aadesharora mrdnegativecrafterazacitidineandvenetoclaxinayoungpatientwithamlunfitforintensiveinductionfollowedbyasct
_version_ 1717381494578610176

Similar Items